Home treatment of mild/moderate COVID-19: To prevent severe disease: IMAGINE?

[1]  A. Marette,et al.  Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes , 2021, Advances in Nutrition.

[2]  Yanqing Fan,et al.  Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia , 2021, Medicine.

[3]  Daryl A Jones,et al.  Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities , 2021, British journal of clinical pharmacology.

[4]  A. Cuvelier,et al.  Cardiopulmonary Exercise Testing to Assess Persistent Symptoms at 6 Months in People With COVID-19 Who Survived Hospitalization – A Pilot Study , 2021, Physical therapy.

[5]  S. J.,et al.  Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials , 2021, Future Journal of Pharmaceutical Sciences.

[6]  J. Laffey,et al.  Awake Proning as an Adjunctive Therapy for Refractory Hypoxemia in Non-Intubated Patients with COVID-19 Acute Respiratory Failure: Guidance from an International Group of Healthcare Workers , 2021, The American journal of tropical medicine and hygiene.

[7]  I. Khanum,et al.  Role of awake prone positioning in patients with moderate-to-severe COVID-19: an experience from a developing country. , 2021, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[8]  R. Guleria,et al.  Effect of proning in patients with COVID-19 acute hypoxemic respiratory failure receiving noninvasive oxygen therapy , 2021, Lung India : official organ of Indian Chest Society.

[9]  M. Peana,et al.  The Role of Diet and Supplementation of Natural Products in COVID-19 Prevention , 2021, Biological trace element research.

[10]  M. Safdar,et al.  Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review , 2021, Food and Chemical Toxicology.

[11]  D. Andreini,et al.  Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients , 2021, JACC: Basic to Translational Science.

[12]  M. Cutolo,et al.  Vitamin D and Lung Outcomes in Elderly COVID-19 Patients , 2021, Nutrients.

[13]  M. Frenkel-Morgenstern,et al.  The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection , 2021, The FEBS journal.

[14]  S. Browne,et al.  Accuracy of Samsung Smartphone Integrated Pulse Oximetry Meets Full FDA Clearance Standards for Clinical Use. , 2021, medRxiv.

[15]  Samantha K. Brenner,et al.  Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019–Related Respiratory Failure* , 2021, Critical care medicine.

[16]  G. Stefano.  Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[17]  S. Pestka.  Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C , 2021, Medical Hypotheses.

[18]  M. Rezaei,et al.  A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms , 2021, EXCLI journal.

[19]  B. Mégarbane,et al.  Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study , 2021, Journal of Infection.

[20]  J. Shaw,et al.  A Novel Large Scale Integrated Telemonitoring Program for COVID-19. , 2021, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[21]  C. Greene,et al.  Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment , 2021, mSystems.

[22]  S. Kateriya,et al.  Mucociliary Respiratory Epithelium Integrity in Molecular Defense and Susceptibility to Pulmonary Viral Infections , 2021, Biology.

[23]  D. Chiumello,et al.  Aspirin in COVID-19 related ARDS: an old, low-cost therapy with a strong rationale. , 2021, Anesthesia and analgesia.

[24]  D. Neuberg,et al.  Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis , 2021, medRxiv.

[25]  Trupti Vakde,et al.  A Rare Case of Acute Pericarditis Due to SARS-CoV-2 Managed With Aspirin and Colchicine , 2021, Cureus.

[26]  Zaw Ali Khan,et al.  Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms , 2021, Journal of inflammation research.

[27]  P. McCullough,et al.  Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. , 2020, Reviews in cardiovascular medicine.

[28]  P. Marik,et al.  Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19 , 2020, Journal of intensive care medicine.

[29]  Yue Zhang,et al.  Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019 , 2020, Frontiers in Molecular Biosciences.

[30]  T. F. Osborne,et al.  Association of Mortality and Aspirin Prescription for COVID-19 Patients at the Veterans Health Administration , 2020, medRxiv.

[31]  Chaofu Wang,et al.  Autopsy and Histologic Findings of Patients with New Coronavirus Pneumonia: The Pathologic Associations with Hypoxemia , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[32]  A. Healy,et al.  Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro , 2020, bioRxiv.

[33]  A. Baig.  Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome , 2020, ACS chemical neuroscience.

[34]  M. Chung,et al.  SARS-CoV-2 Receptors are Expressed on Human Platelets and the Effect of Aspirin on Clinical Outcomes in COVID-19 Patients , 2020, Research square.

[35]  A. Weil,et al.  Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease , 2020, EXPLORE.

[36]  Mika Turkia.  The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19 , 2020, Cureus.

[37]  Jimyung Park,et al.  The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia , 2020, Tuberculosis and respiratory diseases.

[38]  S. Wimalawansa,et al.  Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19 , 2020, Virus Research.

[39]  J. V. van Putten,et al.  Defensive Properties of Mucin Glycoproteins during Respiratory Infections—Relevance for SARS-CoV-2 , 2020, mBio.

[40]  A. Singanayagam,et al.  Why asthma might surprisingly protect against poor outcomes in COVID-19 , 2020, European Respiratory Journal.

[41]  Liyi Huang,et al.  Physical Therapist Management of COVID-19 in the Intensive Care Unit: The West China Hospital Experience , 2020, Physical therapy.

[42]  D. Lidington,et al.  A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients , 2020, Frontiers in Physiology.

[43]  D. Gater,et al.  Initial assessment and management of respiratory infections in persons with spinal cord injuries and disorders in the COVID‐19 era , 2020, Journal of the American College of Emergency Physicians open.

[44]  S. Jakob,et al.  Early Physical Therapist Interventions for Patients With COVID-19 in the Acute Care Hospital: A Case Report Series , 2020, Physical therapy.

[45]  Myasar Alkotaji.  Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2 , 2020, International Journal of Antimicrobial Agents.

[46]  Y. Naito,et al.  Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  M. M. van der Eerden,et al.  Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline , 2020, Clinical Microbiology and Infection.

[48]  M. Nash,et al.  A case for inspiratory muscle training in SCI: potential role as a preventative tool in infectious respiratory diseases like COVID-19 , 2020, Spinal cord series and cases.

[49]  L. Alberghina,et al.  Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro” , 2020, Journal of medical virology.

[50]  F. Vaida,et al.  Smartphone Biosensor With App Meets FDA/ISO Standards for Clinical Pulse Oximetry and Can Be Reliably Used by a Wide Range of Patients , 2020, Chest.

[51]  Huang Yan,et al.  Effect of respiratory rehabilitation training on elderly patients with COVID-19 , 2020, Medicine.

[52]  M. Rela,et al.  COVID-19: Poor outcomes in patients with zinc deficiency , 2020, International Journal of Infectious Diseases.

[53]  C. Bergin,et al.  Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection , 2020, JAC-antimicrobial resistance.

[54]  M. Kong,et al.  Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile , 2020, medRxiv.

[55]  P. Marik,et al.  MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale , 2020, Expert review of anti-infective therapy.

[56]  R. Lee,et al.  First contact: the role of respiratory cilia in host-pathogen interactions in the airways , 2020, American journal of physiology. Lung cellular and molecular physiology.

[57]  A. Abdullahi.  Safety and Efficacy of Chest Physiotherapy in Patients With COVID-19: A Critical Review , 2020, Frontiers in Medicine.

[58]  C. Mantzoros,et al.  Covid-19 and Disparities in Nutrition and Obesity. , 2020, The New England journal of medicine.

[59]  A. Abdollahi,et al.  Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial , 2020, Trials.

[60]  G. Scheuch.  Breathing Is Enough: For the Spread of Influenza Virus and SARS-CoV-2 by Breathing Only , 2020, Journal of aerosol medicine and pulmonary drug delivery.

[61]  Jun Wu.  Tackle the free radicals damage in COVID-19 , 2020, Nitric Oxide.

[62]  B. Chau,et al.  Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for COVID-19 , 2020, American Journal of Physical Medicine & Rehabilitation.

[63]  Adam T Froemming,et al.  A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting , 2020, Mayo Clinic Proceedings.

[64]  P. Freeman,et al.  Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials , 2020, Medical Hypotheses.

[65]  L. Steinman,et al.  Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’1 attack , 2020, Journal of the Neurological Sciences.

[66]  L. Steinman,et al.  Part I. SARS-CoV-2 triggered ‘PANIC’1 attack in severe COVID-19 , 2020, Journal of the Neurological Sciences.

[67]  Zohreh Esam.  Protective potential of expectorants against COVID-19 , 2020, Medical Hypotheses.

[68]  P. Pelosi,et al.  Distinct phenotypes require distinct respiratory management strategies in severe COVID-19 , 2020, Respiratory Physiology & Neurobiology.

[69]  Yuan Wei,et al.  Effects of the Lower Airway Secretions on Airway Opening Pressures and Suction Pressures in Critically Ill COVID-19 Patients: A Computational Simulation , 2020, Annals of Biomedical Engineering.

[70]  B. Sañudo,et al.  Potential Application of Whole Body Vibration Exercise for Improving the Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review from the World Association of Vibration Exercise Experts (WAVex) Panel , 2020, International journal of environmental research and public health.

[71]  H. Momma,et al.  Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells , 2020, Respiratory Investigation.

[72]  M. Hall.  National Heart, Lung, and Blood Institute , 2020, The Grants Register 2021.

[73]  P. Gasque,et al.  Methotrexate an Old Drug with New Tricks , 2019, International journal of molecular sciences.

[74]  A. Yalcin,et al.  Protective effects of benfotiamine on irisin activity in methotrexate-induced liver injury in rats , 2018, Archives of medical science : AMS.

[75]  J. Carey,et al.  Risk of liver disease in methotrexate treated patients , 2017, World journal of hepatology.

[76]  Shin C. Beh,et al.  High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes , 2017, Journal of the Neurological Sciences.

[77]  J. Isaacs,et al.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers , 2016, Nature Reviews Rheumatology.

[78]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[79]  Stephen Brown,et al.  Methotrexate Is a JAK/STAT Pathway Inhibitor , 2015, PloS one.

[80]  Ching-Piao Tsai,et al.  Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study , 2014, Multiple sclerosis.

[81]  J. Seagrave,et al.  Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells , 2012, Respiratory Research.

[82]  A. Huitema,et al.  Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma , 2012, Leukemia & lymphoma.

[83]  C. Guttmann,et al.  A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. , 2010, Archives of neurology.

[84]  R. McIntyre,et al.  Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. , 2009, Journal of the American College of Surgeons.

[85]  A. Bhowmik,et al.  Improving mucociliary clearance in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.

[86]  T. Billiar,et al.  HMGB1: Endogenous Danger Signaling , 2008, Molecular medicine.

[87]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. , 2007, Arthritis and rheumatism.

[88]  N. Zurgil,et al.  Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines , 2005, Inflammation Research.

[89]  H. Cai,et al.  Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[90]  D. Stern,et al.  Advanced Glycation End Product Receptor‐Mediated Cellular Dysfunction , 2005, Annals of the New York Academy of Sciences.

[91]  A. Arroliga,et al.  Effect of airway pressure display on interobserver agreement in the assessment of vascular pressures in patients with acute lung injury and acute respiratory distress syndrome* , 2005, Critical care medicine.

[92]  W. Warwick,et al.  High-frequency chest compression: effect of the third generation compression waveform. , 2004, Biomedical instrumentation & technology.

[93]  K. Woollard,et al.  The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species , 2003, British journal of pharmacology.

[94]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[95]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[96]  H. Weiner,et al.  Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis , 2001, Journal of Neuroimmunology.

[97]  Hyung-Sik Kang,et al.  Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. , 2000, Immunopharmacology.

[98]  A. D. Salman.  COVID-19 PATIENTS , 2021 .

[99]  J. McClung,et al.  Nutrition, Immune Function, and Infectious Disease. , 2021, Medical journal.

[100]  A. Castiglioni,et al.  High-mobility group box 1 (HMGB1) as a master regulator of innate immunity , 2010, Cell and Tissue Research.

[101]  H. Wiedemann.  A perspective on the fluids and catheters treatment trial (FACTT). Fluid restriction is superior in acute lung injury and ARDS. , 2008, Cleveland Clinic journal of medicine.

[102]  H. Weiner,et al.  Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). , 2002, CNS drugs.